← Back to Screener
Keros Therapeutics, Inc. Common Stock (KROS)
Price$11.66
Favorite Metrics
Price vs S&P 500 (26W)-34.42%
Price vs S&P 500 (4W)-3.02%
Market Capitalization$230.10M
P/E Ratio (Annual)2.64x
All Metrics
P/CF (Annual)2.14x
Book Value / Share (Quarterly)$15.51
P/TBV (Annual)3.32x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-43.89%
Cash Flow / Share (Quarterly)$5.42
Price vs S&P 500 (YTD)-46.82%
Net Profit Margin (TTM)35.65%
EPS (TTM)$1.82
10-Day Avg Trading Volume0.35M
EPS Excl Extra (TTM)$1.82
Revenue Growth (5Y)-18.71%
EPS (Annual)$2.30
ROI (Annual)28.70%
Net Profit Margin (5Y Avg)-21395.35%
Cash / Share (Quarterly)$14.71
P/E Basic Excl Extra (TTM)2.64x
Revenue Growth QoQ (YoY)-87.34%
P/E Normalized (Annual)2.64x
ROA (Last FY)25.74%
Revenue Growth TTM (YoY)6774.96%
EBITD / Share (TTM)$1.84
ROE (5Y Avg)-22.40%
Operating Margin (TTM)27.69%
Cash Flow / Share (Annual)$5.42
P/B Ratio0.76x
P/B Ratio (Quarterly)2.05x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)-0.23x
Net Interest Coverage (TTM)-4552.00x
ROA (TTM)13.27%
EV / EBITDA (TTM)-0.84x
EPS Incl Extra (Annual)$2.30
Current Ratio (Annual)15.45x
Quick Ratio (Quarterly)15.22x
3-Month Avg Trading Volume0.44M
52-Week Price Return-13.75%
EV / Free Cash Flow (Annual)-0.54x
P/E Incl Extra (TTM)2.64x
Revenue / Employee (TTM)$3
Tangible BV / Share (Quarterly)$9.97
P/S Ratio (Annual)0.94x
Asset Turnover (Annual)0.72x
52-Week High$22.55
Operating Margin (5Y Avg)-23768.21%
EPS Excl Extra (Annual)$2.30
CapEx CAGR (5Y)39.84%
26-Week Price Return-25.67%
Quick Ratio (Annual)15.22x
13-Week Price Return-40.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.45x
Enterprise Value$-57.311
Revenue / Share Growth (5Y)-28.88%
Asset Turnover (TTM)0.37x
Book Value / Share Growth (5Y)6.58%
Revenue / Employee (Annual)$3
Pretax Margin (Annual)37.65%
Cash / Share (Annual)$14.71
3-Month Return Std Dev51.08%
Net Income / Employee (TTM)$1
ROE (Last FY)28.70%
Net Interest Coverage (Annual)-114790.00x
EPS Basic Excl Extra (Annual)$2.30
Receivables Turnover (TTM)77.37x
EV / Free Cash Flow (TTM)-0.54x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.82
Receivables Turnover (Annual)77.37x
ROI (TTM)14.25%
P/S Ratio (TTM)0.94x
Pretax Margin (5Y Avg)-21391.26%
Revenue / Share (Annual)$6.45
Tangible BV / Share (Annual)$10.07
Forward P/E6.37x
Price vs S&P 500 (52W)-48.84%
P/E Ratio (TTM)2.64x
Year-to-Date Return-42.68%
5-Day Price Return4.66%
EPS Normalized (Annual)$2.30
ROA (5Y Avg)-20.63%
Net Profit Margin (Annual)35.65%
Month-to-Date Return5.71%
Cash Flow / Share (TTM)$-4.93
EBITD / Share (Annual)$1.81
Operating Margin (Annual)27.69%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)2.14x
ROI (5Y Avg)-22.40%
P/E Excl Extra (TTM)2.64x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$1.82
P/TBV (Quarterly)3.12x
P/B Ratio (Annual)2.05x
Pretax Margin (TTM)37.65%
Book Value / Share (Annual)$15.51
Price vs S&P 500 (13W)-43.11%
Beta1.02x
P/FCF (Annual)2.17x
Revenue / Share (TTM)$9.01
ROE (TTM)14.25%
52-Week Low$10.41
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
3.93
3.93
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
KROSKeros Therapeutics, Inc. Common Stock | 0.94x | 6774.96% | — | — | $11.66 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel protein therapeutics for blood disorders with significant unmet needs. The company's lead program, KER-050, targets cytopenias—including anemia and thrombocytopenia—in patients with myelodysplastic syndromes and myelofibrosis.